Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs ...

Johnson & Johnson, which did not apply for the national priority voucher, was granted the ticket based on results from a ...

At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

Novo’s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. Catalent says it worked on more than half of the new drugs approved by the FDA over the past 10 years.

Scientists have discovered another benefit of the blockbuster weight-loss and blood-glucose-lowering drug semaglutide, known ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

The U.S. Food and Drug Administration said on Monday it ‍has granted a national priority voucher to Johnson & Johnson's blood ...

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...